Breaking News

Financial Reports: Roche

By Gil Roth | April 11, 2013

Roche 1Q13

1Q Revenues: $12.5 billion (+4%)

1Q Earnings: not disclosed

Comments: Pharma revenues overall rose 5% to $9.9 billion, with U.S. sales up 13% to $4.2 billion, European sales up 1% to $2.5 billion, Japanese sales down 12% to $888 million, and rest-of-world sales up 6% to $2.3 billion. Rituxan sales were up 6% to $1.8 billion; Herceptin sales rose 11% to $1.7 billion and Avastin sales climbed 11% to $1.6 billion. Tamiflu sales were up 84% to $360 million in the quarter, and Actemra climbed 32% to $256 million.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks